Marc Soco
@msocomd.bsky.social
🇵🇭 Internist • Nephrologist
📍 Cebu, Philippines
✈️ Balancing clinical work with a passion for travel and photography
💡 #NephJC Intern • #GlomCon Alum ‘23-24 • #NephSIM ‘20-21
📍 Cebu, Philippines
✈️ Balancing clinical work with a passion for travel and photography
💡 #NephJC Intern • #GlomCon Alum ‘23-24 • #NephSIM ‘20-21
awesome job @shelliefravel.bsky.social !! #nephJC
a man in a suit and tie is applauding with the words good job written below him
ALT: a man in a suit and tie is applauding with the words good job written below him
media.tenor.com
November 19, 2025 at 3:00 AM
awesome job @shelliefravel.bsky.social !! #nephJC
Reposted by Marc Soco
Reposted by Marc Soco
Sorry will remain a dream for a while!
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
November 19, 2025 at 2:34 AM
Sorry will remain a dream for a while!
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
Reposted by Marc Soco
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals
This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...
jamanetwork.com
November 19, 2025 at 2:12 AM
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
outdated or not, it's amazing how in just a few short years, we’ve moved from purely ‘supportive’ care to therapies that actually work. What a time to be in nephrology! #nephJC
November 19, 2025 at 2:13 AM
outdated or not, it's amazing how in just a few short years, we’ve moved from purely ‘supportive’ care to therapies that actually work. What a time to be in nephrology! #nephJC
Coming from a country where these meds aren’t even available yet, I have to admit... I’m a little envious on behalf of my patients #nephJC
November 19, 2025 at 2:07 AM
Coming from a country where these meds aren’t even available yet, I have to admit... I’m a little envious on behalf of my patients #nephJC
Glad to be here!
We do <1g.
IgAN is the most common GN we identify and they are quite aggressive.
Still hoping for Nefecon to be available soon #NephJC
We do <1g.
IgAN is the most common GN we identify and they are quite aggressive.
Still hoping for Nefecon to be available soon #NephJC
October 29, 2025 at 1:34 AM
Glad to be here!
We do <1g.
IgAN is the most common GN we identify and they are quite aggressive.
Still hoping for Nefecon to be available soon #NephJC
We do <1g.
IgAN is the most common GN we identify and they are quite aggressive.
Still hoping for Nefecon to be available soon #NephJC
Reposted by Marc Soco
We had a lot of discussion with Barratt at his rounds on this.
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
October 29, 2025 at 1:25 AM
We had a lot of discussion with Barratt at his rounds on this.
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC